Drugs and Devices

FDA approves Votrient for advanced soft tissue sarcoma

On April 26, the U.S. Food and Drug Administration (FDA) approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares